N‐terminal truncated pyroglutamyl β amyloid peptide Aβpy3‐42 shows a faster aggregation kinetics than the full‐length Aβ1‐42
暂无分享,去创建一个
[1] H. Lashuel,et al. The Ratio of Monomeric to Aggregated Forms of Aβ40 and Aβ42 Is an Important Determinant of Amyloid-β Aggregation, Fibrillogenesis, and Toxicity* , 2008, Journal of Biological Chemistry.
[2] Hans-Ulrich Demuth,et al. Glutaminyl cyclase inhibition attenuates pyroglutamate Aβ and Alzheimer's disease–like pathology , 2008, Nature Medicine.
[3] J. Shine,et al. Acceleration of Amyloid β-Peptide Aggregation by Physiological Concentrations of Calcium* , 2006, Journal of Biological Chemistry.
[4] Hans-Ulrich Demuth,et al. On the seeding and oligomerization of pGlu-amyloid peptides (in vitro). , 2006, Biochemistry.
[5] J. Danielsson,et al. 15N relaxation study of the amyloid β‐peptide: structural propensities and persistence length , 2006, Magnetic resonance in chemistry : MRC.
[6] C. Dobson,et al. Protein misfolding, functional amyloid, and human disease. , 2006, Annual review of biochemistry.
[7] P. Carey,et al. Raman crystallography and other biochemical applications of Raman microscopy. , 2006, Annual review of physical chemistry.
[8] A. Bonvin,et al. The α‐to‐β Conformational Transition of Alzheimer's Aβ‐(1–42) Peptide in Aqueous Media is Reversible: A Step by Step Conformational Analysis Suggests the Location of β Conformation Seeding , 2006 .
[9] Paul R. Carey,et al. Secondary Structure of α-Synuclein Oligomers: Characterization by Raman and Atomic Force Microscopy , 2006 .
[10] D. Teplow,et al. Conformational dynamics of amyloid beta-protein assembly probed using intrinsic fluorescence. , 2005, Biochemistry.
[11] A. Gliozzi,et al. β-Amyloid Is Different in Normal Aging and in Alzheimer Disease* , 2005, Journal of Biological Chemistry.
[12] C. Ionescu-Zanetti,et al. Mechanism of thioflavin T binding to amyloid fibrils. , 2005, Journal of structural biology.
[13] J. Danielsson,et al. The Alzheimer β‐peptide shows temperature‐dependent transitions between left‐handed 31‐helix, β‐strand and random coil secondary structures , 2005 .
[14] Hai Lin,et al. Amyloid ion channels: a common structural link for protein-misfolding disease. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[15] D. Selkoe,et al. Alzheimer disease: mechanistic understanding predicts novel therapies. , 2004 .
[16] T. Hoffmann,et al. Glutaminyl cyclases unfold glutamyl cyclase activity under mild acid conditions , 2004, FEBS letters.
[17] Clifford J. Woolf,et al. Pain: Moving from Symptom Control toward Mechanism-Specific Pharmacologic Management , 2004, Annals of Internal Medicine.
[18] N. Maiti,et al. Raman spectroscopic characterization of secondary structure in natively unfolded proteins: alpha-synuclein. , 2004, Journal of the American Chemical Society.
[19] Carl W. Cotman,et al. Common Structure of Soluble Amyloid Oligomers Implies Common Mechanism of Pathogenesis , 2003, Science.
[20] G. Krafft,et al. In Vitro Characterization of Conditions for Amyloid-β Peptide Oligomerization and Fibrillogenesis* , 2003, The Journal of Biological Chemistry.
[21] George Perry,et al. Metal binding and oxidation of amyloid-beta within isolated senile plaque cores: Raman microscopic evidence. , 2003, Biochemistry.
[22] Christopher M Dobson,et al. The behaviour of polyamino acids reveals an inverse side chain effect in amyloid structure formation , 2002, The EMBO journal.
[23] M. Franceschi,et al. Protein misfolding in Alzheimer’s and Parkinson’s disease: genetics and molecular mechanisms , 2002, Neurobiology of Aging.
[24] G. Damonte,et al. Pyroglutamate‐modified amyloid β‐peptides – AβN3(pE) – strongly affect cultured neuron and astrocyte survival , 2002 .
[25] L. K. Baker,et al. Oligomeric and Fibrillar Species of Amyloid-β Peptides Differentially Affect Neuronal Viability* , 2002, The Journal of Biological Chemistry.
[26] M. Nagao,et al. Aggregation and neurotoxicity of mutant amyloid β (Aβ) peptides with proline replacement: importance of turn formation at positions 22 and 23 , 2002 .
[27] W. K. Cullen,et al. Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo , 2002, Nature.
[28] Christopher M. Dobson,et al. Kinetic partitioning of protein folding and aggregation , 2002, Nature Structural Biology.
[29] M. Kirkitadze,et al. Identification and characterization of key kinetic intermediates in amyloid beta-protein fibrillogenesis. , 2001, Journal of molecular biology.
[30] Christopher M. Dobson,et al. Amyloid fibrils from muscle myoglobin , 2001, Nature.
[31] B. Ghetti,et al. Neurobiology: Presenilin-1 mutations in Alzheimer's disease , 2000, Nature.
[32] W. Surewicz,et al. Aggregation and fibrillization of the recombinant human prion protein huPrP90-231. , 2000, Biochemistry.
[33] C. Barrow,et al. On-line high-performance liquid chromatography/mass spectrometric investigation of amyloid-beta peptide variants found in Alzheimer's disease. , 1999, Rapid communications in mass spectrometry : RCM.
[34] C. Barrow,et al. The Aβ 3-Pyroglutamyl and 11-Pyroglutamyl Peptides Found in Senile Plaque Have Greater β-Sheet Forming and Aggregation Propensities in Vitro than Full-Length Aβ† , 1999 .
[35] C M Dobson,et al. Designing conditions for in vitro formation of amyloid protofilaments and fibrils. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[36] Y. Ihara,et al. Diffuse plaques associated with astroglial amyloid β protein, possibly showing a disappearing stage of senile plaques , 1998, Acta Neuropathologica.
[37] M. Tabaton,et al. Heterogeneity of water‐soluble amyloid β‐peptide in Alzheimer's disease and Down's syndrome brains , 1997, FEBS letters.
[38] T. Iwatsubo,et al. Amino- and carboxyl-terminal heterogeneity of β-amyloid peptides deposited in human brain , 1996, Neuroscience Letters.
[39] D. Selkoe,et al. Amyloid β-Protein and the Genetics of Alzheimer's Disease* , 1996, The Journal of Biological Chemistry.
[40] P. Lantos,et al. A comparison of beta-amyloid deposition in the medial temporal lobe in sporadic Alzheimer's disease, Down's syndrome and normal elderly brains. , 1996, Neurodegeneration : a journal for neurodegenerative disorders, neuroprotection, and neuroregeneration.
[41] M. Ball,et al. Water-soluble A(N-40, N-42) Oligomers in Normal and Alzheimer Disease Brains (*) , 1996, The Journal of Biological Chemistry.
[42] Peter Davies,et al. Identification of normal and pathological aging in prospectively studied nondemented elderly humans , 1992, Neurobiology of Aging.
[43] G. Glenner,et al. Alzheimer's disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein , 1984 .
[44] N. Sreerama,et al. Estimation of protein secondary structure from circular dichroism spectra: comparison of CONTIN, SELCON, and CDSSTR methods with an expanded reference set. , 2000, Analytical biochemistry.